Abstract Details

Title Serum Insulin-like Growth Factor-1 as a biomarker for Parkinson’s Disease: A systematic review and meta-analysis.

Topic Movement Disorders

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 274

Objective Our aim was to summarize and evaluate the current body of evidence on the serum level of insulin-like growth factor-1 (IGF-1) as a potential diagnostic biomarker for Parkinson’s Disease (PD).

Background IGF-1 is an endocrine, paracrine and autocrine hormone with various functions including tissue growth and proliferation, pro-survival, anti-ageing, antioxidant and neuroprotection, among others. Therefore, there is increasing interest in investigating the possible association of IGF-1 levels with PD. Clinical data on patients with PD have confirmed elevated IGF-1 levels at the onset of the disease, suggesting a compensatory role of IGF-1. However, the results of previous studies are not conclusive.

Design/Methods Pubmed, Web of Science, Scopus, and Cochrane library databases were utilized to identify candidate studies through a systematic literature review according to PRISMA guidelines, without language or time restriction. A random-effects model was chosen, with subgroup analysis and sensitivity analysis conducted to reveal underlying heterogeneity among the included studies.

Results

Our meta-analysis of 14 observational studies showed that PD Patients have higher level of serum IGF-1 in comparison with healthy controls (summary standardized mean difference [SMD]= 0.53, 95% CI= 0.40, 0.67). We found no significant difference between drug naïve patients (Summary SMD= 0.62, 95% CI= 0.40, 0.84) and patients under treatment (Summary SMD= 0.53, 95% CI= 0.35, 0.71). Sub-group analyses showed that the population differences and treatment status were not the sources of heterogeneity.

Conclusions Serum IGF-1 could be used as a potential diagnostic biomarker for PD. Nevertheless, further studies are required to detect the diagnostic cut-off values of IGF-1 and whether the serum or CSF samples have better diagnostic potentiality. Moreover, the association between IGF-1 levels prognosis of PD should be investigated in future studies.

Authors/Disclosures
Mariam M. Alwerdani (Mansoura University) PRESENTER	Miss Alwerdani has nothing to disclose.
	No disclosure on file
Ahmed Hanbal	Mr. Hanbal has nothing to disclose.
	No disclosure on file
	No disclosure on file
Mohamed Fahmy Doheim (University of Pittsburgh)	Mr. Doheim has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��